The “One-stop Public Service Platform for R&D and Evaluation of Cellular and Genetic Therapy Products in the Guangdong-Hong Kong-Macao Greater Bay Area” is a joint initiative established by Lewwin Pharm and three strategic partners: Shenzhen Pregene Biopharma Co., Ltd., which possesses the world’s only dual-core technology platform integrating nanobody development and CAR-T drug development; the Cancer Research Center of the Hong Kong University of Science and Technology, a world-class university; and the Macau Institute for Applied Research in Medicine and Health of the Macau University of Science and Technology. This platform aims to create a one-stop service center that undertakes one or more customized services in the process of cell and gene therapy drug projects, including pilot-scale studies, scale-up transformation, preclinical pharmacological and toxicological research, drug registration and application, and batch production, through an outsourcing service model.